Antagonist of gonadotropin 10 and antibodies targeting surface-expressed FSHR 11-13 were shown the potential role of FSHR in ovarian cancer therapy, evident by suppression of tumorigenesis in mouse model of ovarian cancer. This evidence concerns the gene FSHR and ovarian carcinoma.